X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (290) 290
Patent (48) 48
Publication (45) 45
Conference Proceeding (4) 4
Newspaper Article (4) 4
Book / eBook (2) 2
Book Chapter (2) 2
Dissertation (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (143) 143
oncology (95) 95
male (93) 93
index medicus (91) 91
middle aged (77) 77
cancer (75) 75
aged (69) 69
female (61) 61
adult (49) 49
radiotherapy (48) 48
acyclic or carbocyclic compounds (47) 47
chemistry (47) 47
heterocyclic compounds (47) 47
human necessities (47) 47
hygiene (47) 47
medical or veterinary science (47) 47
metallurgy (47) 47
organic chemistry (47) 47
treatment outcome (40) 40
hematology, oncology and palliative medicine (38) 38
preparations for medical, dental, or toilet purposes (38) 38
prostate cancer (37) 37
clinical trials (35) 35
care and treatment (32) 32
neoplasm staging (32) 32
chemotherapy (31) 31
combined modality therapy (28) 28
disease-free survival (27) 27
prognosis (26) 26
surgery (26) 26
urology & nephrology (26) 26
aged, 80 and over (25) 25
prostatic neoplasms - pathology (25) 25
radiation-therapy (25) 25
research (25) 25
specific therapeutic activity of chemical compounds ormedicinal preparations (25) 25
survival (25) 25
antineoplastic combined chemotherapy protocols - therapeutic use (22) 22
time factors (22) 22
survival rate (21) 21
urology (21) 21
prostatic neoplasms - drug therapy (20) 20
prostatic neoplasms - radiotherapy (20) 20
survival analysis (20) 20
life sciences (19) 19
radiation (19) 19
therapy (19) 19
follow-up studies (18) 18
prostatic neoplasms - mortality (18) 18
risk factors (18) 18
breast cancer (17) 17
breast neoplasms - radiotherapy (17) 17
carcinoma (17) 17
chemotherapy, adjuvant (17) 17
radiation therapy (17) 17
radiology, nuclear medicine & medical imaging (17) 17
trial (17) 17
tumors (17) 17
europe (16) 16
medicine, general & internal (16) 16
specific use of cosmetics or similar toiletpreparations (16) 16
analysis (15) 15
metastasis (15) 15
oncology, experimental (15) 15
quality of life (15) 15
[ sdv.can ] life sciences [q-bio]/cancer (14) 14
cancer therapies (14) 14
disease progression (14) 14
irradiation (14) 14
lymphatic metastasis (14) 14
patients (14) 14
breast neoplasms - surgery (13) 13
health aspects (13) 13
radiotherapy, adjuvant (13) 13
randomized controlled trials as topic (13) 13
kaplan-meier estimate (12) 12
mesh : humans (12) 12
mortality (12) 12
proportional hazards models (12) 12
prostate-specific antigen - blood (12) 12
prostatic neoplasms - surgery (11) 11
prostatic neoplasms - therapy (11) 11
quality assurance (11) 11
risk (11) 11
abridged index medicus (10) 10
adenocarcinoma (10) 10
breast neoplasms - pathology (10) 10
drug administration schedule (10) 10
mesh : aged (10) 10
mesh : middle aged (10) 10
neoplasm metastasis (10) 10
phase-iii (10) 10
radical prostatectomy (10) 10
radiotherapy dosage (10) 10
recurrence (10) 10
research design (10) 10
androgen antagonists - therapeutic use (9) 9
breast-cancer (9) 9
climate change mitigation technologies in the production orprocessing of goods (9) 9
clinical-trials (9) 9
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2012, Volume 380, Issue 9858, pp. 2018 - 2027
Journal Article
European Radiology, ISSN 0938-7994, 10/2018, Volume 28, Issue 10, pp. 4163 - 4173
Journal Article
Lancet Oncology, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 47 - 56
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 2, pp. 184 - 190
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 11, pp. 1066 - 1073
Journal Article
Lancet, The, ISSN 0140-6736, 2008, Volume 371, Issue 9617, pp. 1007 - 1016
Summary Background Surgical resection alone is regarded as the standard of care for patients with liver metastases from colorectal cancer, but relapse is... 
Internal Medicine | ADJUVANT CHEMOTHERAPY | COLON-CANCER | 5-FLUOROURACIL | MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | HEPATIC ARTERIAL INFUSION | PLUS IRINOTECAN | OXALIPLATIN | SURGICAL RESECTION | FOLINIC ACID | FLUOROURACIL | Humans | Middle Aged | Liver Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Liver Neoplasms - surgery | Male | Combined Modality Therapy | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Perioperative Care - methods | Adult | Female | Aged | Colorectal Neoplasms - pathology | Liver Neoplasms - secondary | Chemotherapy | Care and treatment | Colorectal cancer | Leucovorin | Dosage and administration | Excision (Surgery) | Metastasis | Methods | Fluorouracil | Cancer | Heart failure | Hospitals | Medical treatment | Mortality | Liver | Risk | Histology | Angina pectoris | Cancer surgery | Index Medicus | Abridged Index Medicus | Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use | Medical and Health Sciences | Medicin och hälsovetenskap | Colorectal Neoplasms/pathology | Liver Neoplasms/drug therapy/secondary/surgery | MEDICINE | MEDICIN | Organoplatinum Compounds/administration & dosage | Perioperative Care/methods | Fluorouracil/administration & dosage
Journal Article
Lancet Oncology, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 76 - 86
Summary Background Patients with muscle-invasive urothelial carcinoma of the bladder have poor survival after cystectomy. The EORTC 30994 trial aimed to... 
Hematology, Oncology and Palliative Medicine | ADJUVANT CHEMOTHERAPY | PLUS CISPLATIN | METAANALYSIS | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | DOXORUBICIN | METHOTREXATE | VINBLASTINE | CANCER | GEMCITABINE | Lymph Node Excision | Cystectomy - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma - mortality | Male | Vinblastine - administration & dosage | Cystectomy - adverse effects | Urothelium - pathology | Cisplatin - administration & dosage | Time Factors | Urinary Bladder Neoplasms - pathology | Female | Chemotherapy, Adjuvant | Carcinoma - pathology | Doxorubicin - administration & dosage | Carcinoma - drug therapy | Urinary Bladder Neoplasms - mortality | Drug Administration Schedule | Time-to-Treatment | Carcinoma - surgery | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Urinary Bladder Neoplasms - drug therapy | Urinary Bladder Neoplasms - surgery | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Methotrexate - administration & dosage | Urothelium - surgery | Neoplasm Staging | Urothelium - drug effects | Deoxycytidine - analogs & derivatives | Care and treatment | Chemotherapy | Carcinoma | Hospitals | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 862 - 873
Summary Background Since the 1990s, fluorouracil-based adjuvant chemotherapy has significantly reduced the risk of tumour recurrence in patients with stage III... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | 1ST-LINE TREATMENT | THERAPY | ONCOLOGY | BEVACIZUMAB | ADJUVANT TREATMENT | NSABP C-07 | KRAS | COMBINATION | METASTATIC COLORECTAL-CANCER | CHEMOTHERAPY | ras Proteins - genetics | Colonic Neoplasms - genetics | Proto-Oncogene Proteins p21(ras) | Adenocarcinoma - pathology | Colonic Neoplasms - drug therapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Diarrhea - chemically induced | Colonic Neoplasms - surgery | Fluorouracil - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Infusions, Intravenous - adverse effects | Adult | Female | Leucovorin - therapeutic use | Adenocarcinoma - genetics | Chemotherapy, Adjuvant | Cetuximab | Antibodies, Monoclonal, Humanized - adverse effects | Drug Eruptions - etiology | Exons - genetics | Proto-Oncogene Proteins - genetics | Adenocarcinoma - drug therapy | Mucositis - chemically induced | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colonic Neoplasms - pathology | Intention to Treat Analysis | Aged | Neoplasm Staging | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - adverse effects | Adenocarcinoma - surgery | Prevention | Care and treatment | Chemotherapy | Colon cancer | Hospitals | Leucovorin | Product development | Cancer | Index Medicus | Life Sciences
Journal Article